Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.58 |
| ▸ | CSF1R | P07333 | 5/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.48 |
| ▸ | KIT | P10721 | 5/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4901729 | 0.85 | CSF1R (0.55) | EGFRCSF1RHDAC3HDAC4HDAC1 | |
| SCHEMBL27414010 | 0.82 | EGFR (0.52) | EGFRCSF1RKIT | |
| SCHEMBL1899495 | 0.82 | EGFR (0.55) | EGFRCSF1RKIT | |
| SCHEMBL4765653 | 0.81 | CSF1R (0.49) | EGFRCSF1RHDAC3HDAC4HDAC1 | |
| SCHEMBL31565345 | 0.81 | KIT (0.61) | EGFRCSF1RKITRIPK1 | |
| SCHEMBL22195118 | 0.81 | KIT (0.61) | EGFRCSF1RKITRIPK1 | |
| SCHEMBL16546224 | 0.80 | EGFR (0.51) | EGFRCSF1RKDRKIT | |
| SCHEMBL20493380 | 0.80 | KIT (0.70) | EGFRKIT | |
| SCHEMBL6259087 | 0.80 | EGFR (0.53) | EGFRCSF1RKIT | |
| SCHEMBL21408892 | 0.79 | KIT (0.47) | EGFRCSF1RKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838898-A1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2015-02-25 | — | — | EP | disclosed |
| WO-2013157021-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013157021-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013157022-A1 | SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2013-10-24 | — | — | WO | disclosed |
| US-7625894-B2 | Pyrrolo[2,3-d]Pyrimidines as Protein Tyrosine Kinase Inhibitors | NOVARTIS AG (CH) | 2009-12-01 | — | — | US | disclosed |
| US-7625894-B2 | Pyrrolo[2,3-d]Pyrimidines as Protein Tyrosine Kinase Inhibitors | NOVARTIS AG (CH) | 2009-12-01 | — | — | US | disclosed |
| US-7625894-B2 | Pyrrolo[2,3-d]Pyrimidines as Protein Tyrosine Kinase Inhibitors | NOVARTIS AG (CH) | 2009-12-01 | — | — | US | disclosed |
| EP-1718651-B1 | 7H-PYRROLOPYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| EP-1718651-B1 | 7H-PYRROLOPYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-04-22 | — | — | EP | disclosed |
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | CARAVATTI GIORGIO | 2007-06-14 | — | — | US | disclosed |
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | CARAVATTI GIORGIO | 2007-06-14 | — | — | US | disclosed |
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | CARAVATTI GIORGIO | 2007-06-14 | — | — | US | disclosed |
| CN-1922184-A | 7H-pyrrolopyrimidine derivatives | NOVARTIS AG (CH) | 2007-02-28 | — | — | CN | disclosed |
| EP-1718651-A2 | 7H-PYRROLOPYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005077951-A2 | 7H-PYRROLOPYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135460-A1 | 7H-pyrrolopyrimidine derivatives | DPYD, TYMP, DHPS | EGFR 2803/4885CSF1R 3432/4885HDAC3 2390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.